{"organizations": [], "uuid": "5b6109d3f50246792b314c8927d4fba14e431676", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-spring-bank-pharmaceuticals-report/brief-spring-bank-pharmaceuticals-reports-q4-loss-per-share-0-11-idUSASB0C6JM", "country": "US", "domain_rank": 408, "title": "BRIEF-Spring Bank Pharmaceuticals Reports Q4 Loss Per Share $0.11", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.042, "site_type": "news", "published": "2018-02-21T05:35:00.000+02:00", "replies_count": 0, "uuid": "5b6109d3f50246792b314c8927d4fba14e431676"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-spring-bank-pharmaceuticals-report/brief-spring-bank-pharmaceuticals-reports-q4-loss-per-share-0-11-idUSASB0C6JM", "ord_in_thread": 0, "title": "BRIEF-Spring Bank Pharmaceuticals Reports Q4 Loss Per Share $0.11", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-spring bank pharmaceuticals", "sentiment": "negative"}, {"name": "reuters) - spring bank pharmaceuticals inc", "sentiment": "neutral"}, {"name": "pharma", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Spring Bank Pharmaceuticals Inc:\n* SPRING BANK PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATIONAL RESULTS\n* Q4 LOSS PER SHARE $0.11 * SPRING BANK PHARMA - EXPECTS CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 WILL FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO Q4 2019\n* SPRING BANK PHARMA - EXPECTS CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 WILL NOT BE SUFFICIENT TO FUND INITIATION OF ANY PHASE 3 TRIAL FOR INARIGIVIR\n* SPRING BANK PHARMA - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $50.6 MILLION AS OF DEC 31, 2017, COMPARED TO $25.5 MILLION AS OF DEC 31, 2016 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-21T05:35:00.000+02:00", "crawled": "2018-02-21T21:21:41.000+02:00", "highlightTitle": ""}